ET-1, a vasoconstrictive peptide, implicated in a variety of aspects of HF pathogenesis including neurohormonal activation, endothelial dysfunction, cardiac remodeling, inflammation, and fibrosis, has emerged as a promising biomarker in AHF [35]. Here, EDN1 is linked to endothelial dysfunction.